Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.48 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560421 | 0.86 | MRGPRX1 (0.51) | P2RX7MRGPRX1TACR1 | |
| SCHEMBL737438 | 0.83 | P2RX7 (0.49) | P2RX7 | |
| SCHEMBL738172 | 0.83 | P2RX7 (0.50) | P2RX7MRGPRX1TACR1 | |
| SCHEMBL737133 | 0.80 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL16269307 | 0.79 | PRKCQ (0.52) | P2RX7MRGPRX1EPHX2TACR1 | |
| SCHEMBL18677297 | 0.78 | EPHX2 (0.48) | P2RX7EPHX2 | |
| SCHEMBL11618053 | 0.77 | LMNA (0.48) | P2RX7MRGPRX1TACR1 | |
| SCHEMBL30606515 | 0.77 | GLA (0.53) | P2RX7 | |
| SCHEMBL736271 | 0.77 | GLA (0.53) | P2RX7 | |
| SCHEMBL16269143 | 0.76 | CYP2D6 (0.49) | P2RX7MRGPRX1EPHX2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | P2RX7 117/4885MRGPRX1 831/4885EPHX2 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.